Coherus Stock Extends Impressive Rally on Drug Sales

The stock is pacing for its fifth straight win today

Digital Content Manager
Apr 8, 2019 at 10:03 AM
facebook twitter linkedin


The drug maker Coherus BioSciences Inc (NASDAQ:CHRS) is near the top of the Nasdaq today, after the company announced late Friday that preliminary sales of its biosimilar UDENYCA -- used in patients receiving myelosuppressive chemotherapy -- are expected to be between $36 million and $38 million. In response, CHRS stock is up 13.5% at $16.61. 

The security has been on the rise lately, after stringing together four consecutive wins last week -- set for its fifth day in the black today. Looking at the charts, CHRS has nearly doubled off its early January low of $8.32. Today's gap has the shares above short-term resistance in the $15.50 area, and trading in territory not seen since early October.

The news has analysts paying attention, too. J.P. Morgan Securities just lifted its target price to $25 from $22. Sentiment surrounding the stock has already been quite bullish, however. Currently, all five analysts consider CHRS stock a "strong buy," and the consensus 12-month target price of $29 represents a roughly 80.5% premium to current levels. 

Short sellers have started hitting the exits, with short interest down 3.7% in the latest reporting period. Short interest still represents a healthy 17.5% of the stock's available float, though. At CHRS' annual daily pace of trading, it would take over two weeks to cover these pessimistic positions -- which may be contributing to today's outsized gains. 

 

 

 

These investors are using the market's volatility to their advantage and scoring triple-digit gains on many of their trades.

Even in today's sideways bear market, this trading strategy has continued to provide consistency and profitability to a small group of investors. By using this approach, these traders are removing directional risk and still hitting triple-digit returns. If you want access to this strategy, and lower risk with higher returns sounds good to you, then don't wait another minute.

Join us now to receive our next trades the moment they come out!

 

Common mistakes options traders make
 


 


 
Special Offers from Schaeffer's Trading Partners